VIRIDIAN THERAPEUTICS INC (VRDN)

US92790C1045 - Common Stock

23.63  +1.63 (+7.41%)

After market: 23.63 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (10/11/2024, 8:00:02 PM)

After market: 23.63 0 (0%)

23.63

+1.63 (+7.41%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month48.71%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.80B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VRDN Daily chart

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. The company is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Company Info

VIRIDIAN THERAPEUTICS INC

221 Crescent Street, Bldg. 17, Suite 401

Waltham MASSACHUSETTS 80301

P: 16172724600

CEO: Jonathan Violin

Employees: 94

Website: https://www.viridiantherapeutics.com/

VRDN News

News Image11 days ago - Market News VideoTuesday 10/1 Insider Buying Report: VRDN, ENGN
News Imagea month ago - Viridian Therapeutics, Inc.Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
News Imagea month ago - Viridian Therapeutics, Inc.Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
News Imagea month ago - Market News VideoNotable Tuesday Option Activity: BOOT, VRDN, BYON
News Imagea month ago - Market News VideoViridian Therapeutics (VRDN) Shares Cross Above 200 DMA
News Imagea month ago - Investor's Business DailyViridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

The results are also promising for the next-generation version of that drug.

VRDN Twits

Here you can normally see the latest stock twits on VRDN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example